tbuckley/cabot-search huggingface dataset:
Cardiovascular Science in the Service of National Strength
Authors: Michael S. Lauer
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Eric Joseph Newton
Authors: J. Newton
Journal: BMJ (2011)

Born in Surrey but educated in the hills of northern India, Eric was following family tradition when he won an Indian Army scholarship to Madras Medical School. On qualifying he immediately found himself serving as a medical officer in wartime India, and later the Maldives and British Ceylon. These exotic postings were also extremely arduous because of the combined difficulties of war, climate, and tropical diseases. The experience fostered his self reliance, as well as a love of swimming and chess. 

He returned to England in 1946, determined to be a surgeon. Four years later he was appointed resident surgical officer at the Royal Salop Infirmary, where Eileen, his future wife, was already working as sister in charge of the theatres. (For her part, Eileen had qualified SRN in London just in time to be sent to the south coast to receive casualties from Dunkerque. She advanced quickly and, as a very young theatre sister at the Masonic Hospital in London, had worked with many of the famous surgeons of the day before coming to Shrewsbury.) 

In Shrewsbury, Eric found himself looking after neurosurgical cases but felt he could do better for these patients. He …
Brucella abortus in fresh cream and cream products.
Authors: G. I. Barrow, D. C. Miller, D. L. Johnson, C. W. Hingston
Journal: BMJ (1968)

Case 203.-Born in 1911. Started work as a carrier in 1924 for a firm loading lime, cement, tea, and sugar.In 1926 moved to work as storeman to a builder's merchant.Again exposed to lime and cement dust.From 1936 to 1964 worked principally as a plasterer.The histology of this tumour is not known.He never took snuff.Case 204.-Born in 1898.After working as a packman's boy and an apprentice slaughterer , and serving in the Army , he worked as a labourer for grain merchants and was exposed to the dust of cereals and beans.From 1946 to 1961, when an anaplastic carcinoma was diagnosed, he worked in the quarry of a cement works but was not much exposed to dust.He never took snuff.Case 205.-Born in 1896.Started work as a baker's assistant in 1908 and was exposed to flour dust until he left to work at an Army depot in 1914.After service in Army worked at a power station unloading coal trucks ) and later as boilerman, stoker, and storeman , when he was exposed to coal dust and ash.A transitional cell tumour was diagnosed in 1960.He never took snuff.The Oxford Regional Cancer Registry was the principal source of the data reported in this paper and we gratefully acknowledge the assistance of Miss C. Hunt and her staff.We are also grateful to the following for supplying valuable information: Mr. G. Rose, Secretary of the High Wycombe Furniture Manufacturers' Asso- ciation; H.M. Medical Inspectorate of Factories; the Registrars of Births, Deaths, and Marriages for High Wycombe and Banbury; the Registrars General for England and Wales
Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.
Authors: R A Berkman, M J Merrill, W C Reinhold, W T Monacci, A Saxena, W C Clark, J T Robertson, I U Ali, E H Oldfield
Journal: Journal of Clinical Investigation (1993)

Expression of the vascular permeability factor/vascular endothelial growth factor (VEGPF) gene was investigated in human central nervous system (CNS) neoplasms and normal brain. Adsorption of capillary permeability activity from human glioblastoma multiforme (GBM) cell conditioned medium and GBM cyst fluids by anti-VEGPF antibodies demonstrated that VEGPF is secreted by GBM cells and is present in sufficient quantities in vivo to induce vascular permeability. Cloning and sequencing of polymerase chain reaction-amplified GBM and normal brain cDNA demonstrated three forms of the VEGPF coding region (567, 495, and 363 nucleotides), corresponding to mature polypeptides of 189, 165, and 121 amino acids, respectively. VEGPF mRNA levels in CNS tumors vs. normal brain were investigated by the RNase protection assay. Significant elevation of VEGPF gene expression was observed in 81% (22/27) of the highly vascular and edema-associated CNS neoplasms (6/8 GBM, 8/8 capillary hemangioblastomas, 6/7 meningiomas, and 2/4 cerebral metastases). In contrast, only 13% (2/15) of those CNS tumors that are not commonly associated with significant neovascularity or cerebral edema (2/10 pituitary adenomas and 0/5 nonastrocytic gliomas) had significantly increased levels of VEGPF mRNA. The relative abundance of the forms of VEGPF mRNA was consistent in tumor and normal brain: VEGPF495 > VEGPF363 > VEGPF567. In situ hybridization confirmed the presence of VEGPF mRNA in tumor cells and its increased abundance in capillary hemangioblastomas. Our results suggest a significant role for VEGPF in the development of CNS tumor neovascularity and peritumoral edema.
Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance
Authors: Rajat Bannerji, Shinichi Kitada, Ian W. Flinn, Michael Pearson, Donn Young, John C. Reed, John C. Byrd
Journal: Journal of Clinical Oncology (2003)

Purpose: Rituximab has clinical activity in patients with chronic lymphocytic leukemia (CLL) and has a variety of proposed mechanisms, including apoptosis, complement-dependent cell lysis (CDC), and antibody-dependent cellular cytotoxicity (ADCC). Here we examine pretreatment biologic features that promote resistance to apoptosis and CDC in CLL patients and correlate it with clinical outcome to rituximab-based therapy. Patients and Methods: Pretreatment samples from 21 CLL patients treated on a prospective, single-agent rituximab trial were examined for quantitative expression of apoptotic and CDC regulatory proteins, and the level of expression of these proteins was correlated with clinical outcome. Results: Of the 21 patents for whom samples were available, 10 attained a partial response and 11 failed to respond to rituximab therapy. The mean pretreatment expression of Bcl-2, Mcl-1, XIAP, and the ratio of Bcl-2/Bax were higher but not statistically increased in nonresponding patients versus those responding to treatment. In contrast, the pretreatment Mcl-1/Bax ratio was significantly elevated (0.82 ± 0.28 v 0.39 ± 0.29, P &lt; .016) in nonresponding patients compared with patients responding to rituximab therapy. Although pretreatment expression of CD55 and CD59 was not associated with response to rituximab therapy, significantly higher levels of CD59 were observed in the CLL cells that were not cleared from the blood at completion of therapy than the level observed at baseline levels (P = .02). Conclusion: These data indicate that baseline expression of the Mcl-1/Bax ratio, but not CD55 and CD59, predict for clinical response to rituximab therapy in CLL patients. Further study of disrupted apoptosis in CLL as a potential mechanism of resistance to rituximab appears warranted.
Privacy, Confidentiality and Other Legal Considerations in the Establishment of a Centralized Health-Data System
Authors: William J. Curran, Barbara Stearns, Honora Kaplan
Journal: New England Journal of Medicine (1969)

Abstract A major issue confronting health-data systems is the protection of privacy and confidentiality. State laws covering health-information disclosure are geared to specific information rather than to comprehensive coverage of all health data. Federal laws cover only data gathered by federal agencies. Every health-data system should adopt a code of ethics and clearly defined rules and regulations governing protection of information. Violation by employees should be grounds for dismissal, and violation by users should bar future access to the system. Criminal as well as civil penalties for wrongful disclosure should be adopted by statute. The system should make use of interagency agreements. A privacy committee and a method of public surveillance should be established. The organizational structure should take the form of a consortium of the contributing agencies to ensure the continuing co-operation and support of these agencies and the greatest public acceptance of the system.
Corrigendum to “The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study” [Eur Urol 2010;57:123–31]
Authors: Claus G. Roehrborn, Paul Siami, Jack Barkin, Ronaldo Damião, Kim Major-Walker, Indrani Nandy, Betsy B. Morrill, R. Paul Gagnier, Francesco Montorsi
Journal: European Urology (2010)
Spondyloarthropathy and Hidradenitis Suppurativa
Authors: Ralph E. Bennett, William S. Wilke, Dale P. Murphy
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 January 1983Spondyloarthropathy and Hidradenitis SuppurativaRALPH E. BENNETT, M.D., WILLIAM S. WILKE, M.D., DALE P. MURPHY, M.D.RALPH E. BENNETT, M.D.Search for more papers by this author, WILLIAM S. WILKE, M.D.Search for more papers by this author, DALE P. MURPHY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-1-112_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Rosner and associates (1) recently reported ten patients with spondyloarthropathy associated with hidradenitis suppurativa and acne conglobata. We report a case that is similar except for the patient's developing arthritis 28 years before he developed hidradenitis suppurativa.A 47-year-old black man had intermittent swelling of both knees and several proximal interphalangeal joints at the age of 11. These symptoms remained mild and episodic until he was 33 years old, when he developed persistent pain and swelling in many small and large joints. During several exacerbations of arthritis, he had diffuse alopecia. The patient took prednisone, 15 mg/d,...Reference1. ROSNERRICHTERHUETTNERKUFFNERWISNIESKIBURG IDTGJC. Spondyloarthropathy associated with hidradenitis suppurativa and acne conglobata. Ann Intern Med. 1982;97:520-5. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: RALPH E. BENNETT, M.D.; WILLIAM S. WILKE, M.D.; DALE P. MURPHY, M.D.Affiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySpondyloarthritis Associated with Acne Conglobata, Hidradenitis Suppurativa and Dissecting Cellulitis of the Scalp: A Review with Illustrative CasesHidradenitis Suppurativa: Surgical and Other Management TechniquesL’hidradénite suppurée ou maladie de Verneuil : une cause de spondylarthrite ?La génétique de l’hidradénite suppuréeGenetics of Hidradenitis SuppurativaDissecting cellulitis of the scalp with associated spondylarthropathy: case report and reviewAcne inversa (alias hidradenitis suppurativa)Hidradenitis suppurative and monoarthriatis of the hipThe SAPHO syndromeMUSCULOSKELETAL FEATURES OF ACNE, HIDRADENITIS SUPPURATIVA, AND DISSECTING CELLULITIS OF THE SCALPDermatologische Erkrankungen des AnorektumsAffections associées : causalité ou complications?Associated Diseases: Causality or Complications? 1 January 1983Volume 98, Issue 1Page: 112-112KeywordsAcneArthralgiaArthritisInflammationKnees ePublished: 1 December 2008 Issue Published: 1 January 1983 PDF downloadLoading ...
Keratin 17 mutation in pachyonychia congenita type 2 with early onset sebaceous cysts
Authors: Y-G. Feng, S-X. Xiao, X-R. Ren, W-Q. Wang, A. Liu, M. Pan
Journal: British Journal of Dermatology (2003)

Pachyonychia congenita (PC) is a group of autosomal dominant ectodermal dysplasias caused by mutations in four differentiation-specific keratin genes. Two major clinical subtypes of PC have been generally recognized. Symmetrically thickened fingernails and toenails are the defining characteristic of PC type 2 (PC-2) with onset at infancy. Pilosebaceous cysts are the best hallmark of PC-2, but they usually occur at puberty.To report a Chinese pedigree of PC-2 with unusually early onset sebaceous cysts and to explore the genetic mutation and its phenotype.Exon 1 of keratin 17 was amplified by polymerase chain reaction (PCR) from genomic DNA from the three patients in the pedigree, the proband, his half-sister and his younger son, two unaffected members in the pedigree and 50 unrelated and unaffected people. PCR products were directly sequenced to detect the mutation.Direct sequencing of the PCR products revealed a heterozygous 275A-->G mutation in all three affected members. This mutation predicts the substitution of asparagine by serine in codon 92 (N92S) located in the 1A domain of keratin 17.Mutation in the 1A domain of keratin 17 underlies the affected members' phenotype, PC-2 with early onset sebaceous cysts and late-onset thickened fingernails and toenails. The onset of the cysts is very early in some people within this family and the age at onset of thickened fingernails and toenails is variable within the family, implying the existence of modifying factors.
Relationship Between Postoperative Cardiac Troponin I Levels and Outcome of Cardiac Surgery
Authors: Bernard L. Croal, Graham S. Hillis, Patrick H. Gibson, Mohammed T. Fazal, Hussein El-Shafei, George Gibson, Robert R. Jeffrey, Keith G. Buchan, Douglas West, Brian H. Cuthbertson
Journal: Circulation (2006)

Background— Cardiac surgery may be associated with significant perioperative and postoperative morbidity and mortality. Underlying pathology, surgical technique, and postoperative complications may all influence outcome. These factors may be reflected as a rise in postoperative troponin levels. Interpretation of troponin levels in this setting may therefore be complex. This study assessed the prognostic significance of such measurements, taking into account potential confounding variables. Methods and Results— One-thousand three hundred sixty-five patients undergoing cardiac surgery underwent measurement of cardiac troponin I (cTnI) at 2 and 24 hours after surgery. The relationship of these measurements to subsequent mortality was established. After taking into account all other variables, cTnI levels measured at 24 hours were independently predictive of mortality at 30 days (odds ratio [OR] 1.14 per 10 μg/L, 95% confidence interval [CI] 1.05 to 1.24, P =0.002), 1 year (OR 1.10 per 10 μg/L, 95% CI 1.03 to 1.18, P =0.006), and 3 years (OR 1.07 per 10 μg/L, 95% CI 1.00 to 1.15, P =0.04). Cardiac TnI levels in the highest quartile at 24 hours were associated with a particularly poor outcome. Conclusions— cTnI levels measured 24 hours after cardiac surgery predict short-, medium-, and long-term mortality and remain independently predictive when adjusted for all other potentially confounding variables, including operation complexity.
Medicines information leaving blind people behind?
Authors: D K Raynor, N Yerassimou
Journal: BMJ (1997)

All new medicines in Britain must now come with a comprehensive manufacturer's leaflet inside the pack. Within two years all existing medicines will also include such a leaflet.1 This is the most important change for over a decade in the provision of information to patients. However, the claimed benefits from these leaflets will not be available to the 1.7 million people in Britain with impaired vision.2 Most visually impaired people are elderly,2 a group that is prescribed nearly half of all prescription drugs.3 Most live alone and have to rely on friends, families, or neighbours to read information for them. When this is medical information, the preference for privacy and confidentiality is obvious.

If the move towards patient empowerment is to succeed, patients need information to guide their choices.4 The Royal National Institute for the Blind's “See it Right” campaign makes the point that visually impaired people have a right to equal access to information, including medical information.5 We live in an …
No-Fault Compensation for Medical Injuries
Authors: David M. Studdert, Troyen A. Brennan
Journal: JAMA (2001)

Leading patient safety proposals promote the design and implementation of error prevention strategies that target systems used to deliver care and eschew individual blame. They also call for candor among practitioners about the causes and consequences of medical injury. Both goals collide with fundamental tenets of the medical malpractice system. Thus, the challenge of addressing error in medicine demands a thorough reconsideration of the legal mechanisms currently used to deal with harms in health care. In this article, we describe an alternative to litigation that does not predicate compensation on proof of practitioner fault, suggest how it might be operationalized, and argue that there is a pressing need to test its promise. We tackle traditional criticisms of "no-fault" compensation systems for medical injury-specifically, concerns about their cost and the presumption that eliminating liability will dilute incentives to deliver high-quality care. Our recent empirical work suggests that a model designed around avoidable or preventable injuries, as opposed to negligent ones, would not exceed the costs of current malpractice systems in the United States. Implementation of such a model promises to promote quality by harmonizing injury compensation with patient safety objectives, especially if it is linked to reforms that make institutions, rather than individuals, primarily answerable for injuries.
Treating heartburn in pregnancy: comparison of acid and alkali mixtures.
Authors: R D Atlay, A R Weekes, G D Entwistle, D J Parkinson
Journal: BMJ (1978)

A randomised crossover trial was performed in 55 pregnant women who complained of heartburn to see whether alkali or acid treatment alleviated it. Each woman was given a week's treatment with an acid mixture, an alkali mixture, and a placebo in randomised order. Both acid and alkali mixtures were better than placebo, but there was no significant difference between the acid and alkali treatments. Together with the inconsistent reports of some patients, these findings suggest that both acid reflux and bile regurgitation may cause heartburn in pregnant women and that other factors may also play a part. Because the cause of heartburn may be difficult to determine, treatment should be empirical. If the patient does not respond to seven days' acid treatment an alkali mixture should be prescribed; there is a 98% chance that one of these treatments will relieve symptoms.
PEMPHIGUS VULGARIS: FAILURE OF TREATMENT WITH RIBOFLAVIN AND SMALLPOX VACCINE
Authors: Stewart Wolf
Journal: JAMA (1941)

An encouraging report of the treatment of pemphigus vulgaris was recently made by Topping and Knoefel.<sup>1</sup>They administered to their patient orally a flavin concentrate containing 970 Sherman-Bourquin units, or approximately 2.5 mg. of riboflavin daily. This patient had previously been treated by them with neoarsphenamine and sulfanilamide without success. After the administration of riboflavin had been started, however, the lesions cleared up and the patient remained well for several weeks. Later, after treatment was discontinued, the patient suffered a recurrence.<sup>2</sup>When the drug was resumed, this time in the dose of 5 mg. daily, the lesions cleared up again, and the patient has been apparently well since, nearly fourteen months after the institution of riboflavin therapy.<sup>2</sup> On the strength of this favorable report, and since pemphigus is still considered a fatal disease, a patient in the New York Hospital suffering from pemphigus was treated for eleven
Affinity Labeling of Hormone-Specific Proteins*
Authors: FREDERICK SWEET, GARY L. MURDOCK
Journal: Endocrine Reviews (1987)

AFFINITY labeling for studying the amino acid topography of specific binding sites in biologically important proteins has emerged as an important biochemical technique during the past three decades. Hormone-specific proteins have been the subjects of affinity labeling during the past two decades, beginning with the analysis of the amino acids which constitute the catalytically active site of the enzymes involved in steroid biosynthesis. More recently, hormone-specific receptor and transport proteins have been characterized, and the amino acid compositions of their binding sites have been described by affinity labeling. The reagents used for affinity labeling are analogs of hormones which produce active site-directed irreversible inhibition in the proteins which they attack. Therefore, they have been regarded as potential new drugs for controlling fertility, treating endocrine disorders, and for treating hormone-sensitive cancers. The three major categories of affinity labeling hormone analogs have been classified according to the reagent groups they possess and the mechanisms by which they inhibit the proteins. Affinity alkylating analogs possess a reagent group which at all times is reactive toward certain amino acids. Photoaffinity labeling ana- logs are only reactive while they absorb light energy, and in the energized state they can react with most amino acids. Autoinactivating substrates have thus far only been used with enzymes because they are reactive toward amino acids only after an enzyme has converted the substrates to a reactive form. All three categories of affinity labeling hormone analogs cause irreversible inhibition when they react with an amino acid at a binding site of a hormone-specific protein.